Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02492711 · ClinicalTrials.gov registry record · Phase 3
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
A Phase 3 study, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 3
- Development phase
- 624
- Enrollment target
NCT02492711 is a Phase 3 study that has completed, run by MacroGenics. The registered enrollment target is 624 participants.
The verdict
NCT02492711, a Phase 3 study, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 624 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with trastuzumab plus chemotherapy. A non-randomized sub-study cohort of approximately 88 patients will be enrolled to evaluate the safety of a reduced margetuximab infusion rate in patients receiving margetuximab either as monotherapy or in combination with chemotherapy.
Interventions
- BIOLOGICAL Trastuzumab
- BIOLOGICAL Margetuximab
- DRUG Physician's choice of chemotherapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 624 participants |
| Start Date | 2015-08-24 |
| Est. Completion | 2022-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02492711
The ClinicalTrials.gov registry entry for NCT02492711 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 624 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT02492711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02492711 about?
NCT02492711 is a clinical study titled "Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer". The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with trastuzumab plus chemotherapy. A non-randomized sub-study cohort of a...
What is the current status of trial NCT02492711?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 624 participants. The study started on 2015-08-24. Estimated completion is 2022-06-14.
What interventions are being tested in trial NCT02492711?
The interventions under investigation include: Trastuzumab (BIOLOGICAL), Margetuximab (BIOLOGICAL), Physician's choice of chemotherapy. (DRUG).
Who is sponsoring clinical trial NCT02492711?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.